Compare Pfizer Inc (PFE) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Primo Brands Corporation Class A Common Stock — how do they compare? Pfizer Inc trades at $29.52 (market cap $161.70B), while Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B). The key difference: Pfizer Inc is far larger — about 23.6× Primo Brands Corporation Class A Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| PFE | PRMB | |
|---|---|---|
Market Cap | $161.70B | $6.84B |
Volume | 26,828,084 | 2,864,594 |
Sector | Health | Consumer Staples |
52-Week High | $29.21 | $25.39 |
52-Week Low | $23.67 | $14.46 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $213.20B | $12.17B |
Dividend Yield | 6.06% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.
Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
